Associated tags: Patent, Patient, Family, Pharmaceutical industry, TSX, Reunion, Toronto Stock Exchange, SEDAR, Depression, EDGAR
Locations: ONTARIO, TORONTO, ON, CA, REUNION, MA
Education,
Safety,
PPD,
Certification,
Neuroscience,
Partnership,
Grammatical mood,
Depression,
Appetite,
Mental health,
Patient,
Mother,
Clinical trial,
Sleep,
Woman NEW YORK, April 15, 2024 /PRNewswire-PRWeb/ -- Fluence, a global leader in education, training, and certification for practitioners of psychedelic medicine, and Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced a strategic partnership to support the Phase 2 clinical study evaluating the safety and efficacy of RE104 in postpartum depression (PPD). Fluence will bring its expertise to Reunion Neuroscience's study monitors, ensuring the highest standards of therapeutic support and rigorous, scalable training within the clinical trial context.
Key Points:
- Fluence will bring its expertise to Reunion Neuroscience's study monitors, ensuring the highest standards of therapeutic support and rigorous, scalable training within the clinical trial context.
- This partnership with Fluence is a significant step towards our goal to meaningfully transform mental health treatment.
- Reunion's lead asset, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound.
- "We are thrilled to partner with Reunion Neuroscience in their groundbreaking study on RE104 for postpartum depression," said Dr. Elizabeth Nielson, Co-founder and Chief Visionary Officer at Fluence.
The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound.
Key Points:
- The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound.
- In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile.
- Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression ( NCT06342310 ).
- Details of the presentations are as follows:
Location: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor Level
The poster will be available on Reunion’s website on Friday, April 12, 2024.
Retrieved on:
Thursday, October 5, 2023
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences.
Key Points:
- WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences.
- Please contact your representative to schedule a 1x1 meeting with the company.
Retrieved on:
Monday, September 18, 2023
PPD,
Pregnancy,
Reunion,
Female,
Death,
Patient,
Risk,
Child,
Heel,
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Mental health,
IND,
Food,
Safety,
Pharmaceutical industry,
Nursing The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD.
Key Points:
- The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD.
- The study is expected to begin in Q4 2023 with a targeted data readout in late 2024.
- “Mental health conditions unfortunately remain the leading cause of pregnancy related deaths.
- Reunion is committed to making a significant difference in improving outcomes in this patient population and other mental health disorders.”
Ontario Superior Court of Justice,
Share,
BioImpacts,
Toronto Stock Exchange,
Canada Business Corporations Act,
Reunion,
Share (finance),
Arrangement,
US,
TSX,
DRS,
MPM,
Security (finance) TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.
Key Points:
- TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.
- Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive US$1.12 in cash for each Share held immediately prior to the effective time of the Arrangement.
- With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023.
- The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws.
Ontario Superior Court of Justice,
Share,
Model Business Corporation Act,
Reunion,
Arrangement,
EDGAR,
Canada Business Corporations Act,
US,
SEDAR,
TSX,
Security (finance),
MPM As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023.
Key Points:
- As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023.
- Assuming that the remaining conditions precedent are satisfied or waived, Reunion anticipates that closing of the Arrangement will occur on or about July 21, 2023.
- On May 31, 2023, Reunion and affiliates of MPM entered into a definitive arrangement agreement (the "Arrangement Agreement"), whereby affiliates of MPM would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million.
- Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding common shares ("Shares") of Reunion will be entitled to receive US$1.12 in cash for each Share held immediately prior to the effective time of the Arrangement.
Ontario Superior Court of Justice,
Final order,
Model Business Corporation Act,
Reunion,
Arrangement,
Meeting,
EDGAR,
Canada Business Corporations Act,
US,
SEDAR,
TSX,
Security (finance),
MPM,
Proxy,
Holding company At the Meeting, shareholders voted in favour of a special resolution (the "Arrangement Resolution") to approve the proposed plan of arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, whereby affiliates of MPM BioImpact would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million.
Key Points:
- At the Meeting, shareholders voted in favour of a special resolution (the "Arrangement Resolution") to approve the proposed plan of arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, whereby affiliates of MPM BioImpact would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million.
- Pursuant to the terms and conditions of the Arrangement, all Shareholders will be entitled to receive US$1.12 in cash for each common share held immediately prior to the effective time of the Arrangement.
- The Arrangement Resolution required the approval of not less than two-thirds (66 2/3%) of the votes cast by shareholders present in person or represented by proxy at the Meeting.
- Shareholders approved the Arrangement Resolution at the Meeting, with 99% of the votes cast at the Meeting in favour of the Arrangement.
Empyrean,
Psilocybin,
BioImpacts,
Toronto Stock Exchange,
PD,
Glenmark Pharmaceuticals,
D.O,
Reunion,
Pharmacovigilance,
Biotechnology,
Scientific Research and Experimental Development Tax Credit Program,
Calendar,
Woman,
Arrangement,
Bristol Myers Squibb,
FAPA,
Trial of the century,
ASCP,
Eli Lilly,
Spinout,
Annual general meeting,
Drug discovery,
TSX,
Chief Medical Officer of Hungary,
Johnson & Johnson,
Research,
Society,
MPM,
Scientific method,
Pharmaceutical industry,
Cryptocurrency TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update.
Key Points:
- Shareholders will be entitled to receive US$1.12 in cash for each share held immediately prior to the effective time of the take-private transaction.
- The transaction is currently contemplated to close in the third calendar quarter of 2023, subject to satisfaction of certain closing conditions.
- On April 3, 2023, Reunion announced that it appointed seasoned pharmaceutical executive, Fred Grossman, D.O., FAPA, to its Board of Directors.
- Drug Effect Questionnaire and Mystical Effect Questionnaire scores observed at these dose levels indicate the potential for therapeutic effect.
Psilocybin,
PK,
Ontario Superior Court of Justice,
LLP,
Share,
BioImpacts,
PI,
Canada Business Corporations Act,
Committee,
Calendar,
Morgan, Lewis & Bockius,
Woman,
Meeting,
ASCP,
Wilmer Cutler Pickering Hale and Dorr,
Science,
US,
Bank,
SEDAR,
Annual general meeting,
TSX,
Oppenheimer,
MPM,
Society,
Court,
Pharmaceutical industry,
Security (finance),
Property management,
Shareholder,
Arrangement TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has entered into a definitive arrangement agreement dated May 31, 2023 (the "Arrangement Agreement") with MPM BioImpact (“MPM”), a world-leading biotechnology investment firm, whereby affiliates of MPM would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement").
Key Points:
- “We believe that this all-cash transaction maximizes value and is in the best interest of our shareholders,” said Greg Mayes, Reunion President and CEO.
- Upon completion of the transaction, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM.
- McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM.
- The adverse event profile of RE104 was similar to that of psilocybin, with no serious adverse events.
The Notice has no immediate effect on the listing of the Company’s common shares on the Nasdaq Global Select Market.
Key Points:
- The Notice has no immediate effect on the listing of the Company’s common shares on the Nasdaq Global Select Market.
- The letter also indicated that, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company will be provided with a compliance period of 180 calendar days, or until October 16, 2023 (the “Compliance Period”), to regain compliance.
- In order to regain compliance with NASDAQ’s minimum bid price requirement, the Company’s common shares must maintain a minimum closing bid price of at least U.S. $1.00 for a minimum of ten consecutive business days during the Compliance Period.
- However, if it appears to NASDAQ that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, the Company may face delisting.
